Flecainide

Flecainide is a prescription antiarrhythmic drug placed in class Ic of the Vaughan Williams classification, the group of agents that most strongly slow the rapid inward sodium current of heart cells ^[1][3]. Chemically it is a fluorinated benzamide carrying two trifluoromethyl groups, with the molecular formula C17H20F6N2O3, and it has long been marketed under the trade name Tambocor ^[1]. Taken by mouth it is almost completely absorbed, is broken down partly by the liver enzyme CYP2D6, and has an elimination half-life of roughly a day ^[1].

The drug was developed in the 1970s and received approval from the United States Food and Drug Administration in 1985 ^[1]. Its patent later expired, and generic versions became available in 2004 ^[1]. It remains in regular clinical use; as of the early 2020s it still ranked among the few hundred most commonly prescribed medicines in the United States ^[1].

Flecainide is used to control a range of fast heart rhythms that arise above the ventricles, including atrioventricular nodal reentrant tachycardia and the arrhythmias of Wolff-Parkinson-White syndrome, and it is a recognised option for restoring and maintaining normal rhythm in atrial fibrillation ^[1][4]. It can also be given for selected ventricular tachycardias, and cardiologists sometimes administer it deliberately to unmask the electrocardiographic pattern of Brugada syndrome as a diagnostic test ^[1]. After a quarter century of use, reviewers concluded that in patients whose hearts are structurally normal, flecainide is both effective and reasonably safe for managing atrial fibrillation ^[4].

The most important limit on its use comes from the Cardiac Arrhythmia Suppression Trial, a large study published in 1991 that tested whether suppressing extra beats after a heart attack would prevent sudden death ^[2]. Instead the trial found excess deaths among patients taking flecainide or the related drug encainide, and that arm of the study was halted early ^[2]. As a result, flecainide is avoided in people with a history of myocardial infarction, reduced heart function, or other significant structural heart disease, and is reserved chiefly for those with otherwise healthy hearts ^[2][4].

Flecainide is a prescription Class Ic antiarrhythmic, not a supplement, and its risk profile is defined by the Cardiac Arrhythmia Suppression Trial, in which flecainide and related agents increased mortality when used to suppress ventricular ectopy after myocardial infarction; the excess risk was attributed to proarrhythmia, amplified by adrenergic tone in diseased tissue.

For this reason flecainide is contraindicated in people with structural or ischemic heart disease and is used only in patients without significant structural heart disease, with baseline and follow up electrocardiography, exercise testing, and often therapeutic drug monitoring. Extracardiac effects include dizziness, visual disturbances, and, rarely, vestibular symptoms. Any use of flecainide for cognition, neuroprotection, or as an adjunct to stimulants is off label and theoretical, is not endorsed by cognitive outcome trials, and must involve a physician given the drug's cardiac risk and interaction potential. Not medical advice.

Flecainide is metabolized primarily by cytochrome P450 2D6 (CYP2D6), making its clearance highly sensitive to enzyme inhibition. Coadministration with CYP2D6 inhibitors such as paroxetine increases systemic flecainide exposure and prolongs the QT interval; in one study, paroxetine coadministration resulted in an additional 6.5 to 6.7 millisecond increase in the corrected QT interval compared to flecainide alone, with more pronounced effects in extensive metabolizers. ^[28] Genetic polymorphisms in CYP2D6 substantially affect flecainide disposition; patients with reduced CYP2D6 activity show decreased clearance and higher concentrations. Additionally, case reports describe flecainide toxicity triggered by herbal supplements that inhibit CYP2D6, highlighting the clinical significance of this metabolic pathway in patients taking concurrent CYP2D6 inhibitors. ^[29]

Checking a whole stack? Run it through interactions + stacks.

Flecainide was developed by Riker Laboratories, later part of 3M, in the 1970s and reached the market as a Class Ic antiarrhythmic, receiving Food and Drug Administration approval in 1985 under the brand name Tambocor. Its early career was profoundly shaped by the Cardiac Arrhythmia Suppression Trial (CAST), which in 1989 found that suppressing arrhythmias with drugs of this class actually increased mortality in patients recovering from heart attacks; the result became a landmark lesson in evidence-based medicine and narrowed the drug's use to patients without structural heart disease.

Years later, research by Bjorn Knollmann and colleagues, published in 2009, revealed that flecainide directly stabilizes the cardiac ryanodine receptor RyR2 and can prevent catecholaminergic polymorphic ventricular tachycardia, an inherited arrhythmia. That discovery of a distinct calcium-handling mechanism opened new scientific interest. The proposed cognition and neuroprotection applications discussed here remain investigational and are not approved uses.

Flecainide is a well-established and effective antiarrhythmic with a long clinical record for suppressing supraventricular and ventricular arrhythmias in appropriately selected patients. What makes it scientifically intriguing beyond cardiology is its second, more recently appreciated mechanism; it directly stabilizes the ryanodine receptor RyR2 and curbs pathological intracellular calcium leak, the same kind of leak implicated in synaptic dysfunction, tau pathology, and cognitive decline in Alzheimer's models.

A separate line of work shows that its sodium-channel blockade can protect axons from degeneration in neuroinflammatory models, offering a distinct neuroprotective rationale. For researchers interested in calcium homeostasis as a bridge between the heart and the brain, flecainide is a genuinely compelling molecule. It must be stated plainly that human cognitive-enhancement evidence is preclinical or theoretical, and that flecainide remains a potent cardiac drug with a documented proarrhythmic risk in people with structural heart disease.